Retension Pharmaceuticals, Inc. (RTSN)
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Retension Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 8.33M shares outstanding
USRetension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension.
The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Leadership
Eric Keller
Co-founder, CEO & Director
Paul Sweetnam
Co-Founder, CSO & Secretary
Michael Joseph Berendt
Executive Chairman
Alexander Duke Schwartz
Chief Financial Officer
Employees
--
Country
US
Sector
Healthcare
Website
retensionpharmaceuticals.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Keller Eric L. | CHIEF EXECUTIVE OFFICER | Grant/Award | 40.9K | -- | Oct 22, 2026 |
 BERGER FRANKLIN M | Director | Purchase | 10.0K | $120.0K | Oct 13, 2026 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Purchase | 20.8K | $249.6K | Oct 13, 2026 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Conversion of Derivative | 9.7K | -- | Oct 13, 2026 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Conversion of Derivative | 31.4K | -- | Oct 13, 2026 |
 BERENDT MICHAEL J | Director | Conversion of Derivative | 4.0K | -- | Oct 13, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
PVG ASSET MANAGEMENT CORP · may incl. warrants· filed Oct 2026 | 1.0M | 12.0% | 13G |
The B Group, Inc. · joint filing· may incl. warrants· filed Oct 2026 | 833.3K | 10.0% | 13G |
Laurence W. Lytton · may incl. warrants· filed Oct 2026 | 617.2K | 7.4% | 13G |
Eric Keller · may incl. warrants· filed Oct 2026 | 598.6K | 7.2% | 13D |
 Sweetnam Paul CHIEF SCIENTIFIC OFFICER | 406.6K | 4.9% | FORM 4 |
 BERGER FRANKLIN M Director | 12.5K | 0.2% | FORM 4 |
 BERENDT MICHAEL J Director | 6.7K | 0.1% | FORM 4 |
 Olds Donald Director | 5.6K | 0.1% | FORM 4 |
 Bisson Sabine CHIEF OPERATING OFFICER | 4.1K | 0.0% | FORM 4 |
Insiders
- Keller Eric L.CHIEF EXECUTIVE OFFICER
- BERGER FRANKLIN MDirector
- BERENDT MICHAEL JDirector
- Sweetnam PaulCHIEF SCIENTIFIC OFFICER
- Olds DonaldDirector
- Bisson SabineCHIEF OPERATING OFFICER
- Cheruvu PavanDirector
based on 8.33M shares outstanding
US30d Avg
187.08K
60d Avg
187.08K
90d Avg
187.08K